|
Accueil > Actualité
AstraZeneca: CHMP recommends apprival of Enhertu
(CercleFinance.com) - AstraZeneca has announced that the European Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Enhertu (trastuzumab deruxtecan) as monotherapy for the treatment of adult patients with HER2-activated advanced non-small cell lung cancer (NSCLC) requiring systemic therapy after platinum-based chemotherapy with or without immunotherapy.
This opinion is based on the main results of a trial demonstrating a confirmed objective response rate (ORR) of 49.0%. AstraZeneca said that HER2-mutant non-small cell lung cancer is an aggressive form of lung cancer that often affects younger patients and has a poor prognosis, with limited approved therapies. This milestone recognises the unmet need in the European Union and, if approved, Enhertu will provide the first targeted treatment option for these patients. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
11/12/2023 10:41
Bristol Myersrésultats positifs autour du Breyanzi 11/12/2023 10:30 Rochede nouvelles données positives au congrès ASH 11/12/2023 10:20 Holcimreçoit deux prix lors de la COP28 11/12/2023 10:10 Pharnextle titre chute après une étude clinique décevante 11/12/2023 10:03 Forsee Powertirage d'une tranche auprès de la BEI 11/12/2023 09:51 Alstoma inauguré le tram-train Citadis Dualis en Essonne Tous les articles sociétés |
